Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study as 1L Therapy for Nasopharyngeal Carcinoma

 Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study as 1L Therapy for Nasopharyngeal Carcinoma

Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study as 1L Therapy for Nasopharyngeal Carcinoma

Shots:  

  • The P-III Jupiter-02 Study involve assessing of Toripalimab vs PBO in combination with + Gemcitabine/ Cisplatin for 1L treatment of 289 patients with recurrent or metastatic NPC
  • The study resulted in meeting its pre-specified 1EPs of PFS and has expanded the PFS. The company will submit the BLA to NMPA & other countries
  • Toripalimab is a PD-1 mAB and has received NMPA’s approval for metastatic melanoma on Dec 17, 2018, in China

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Junshi

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post